Hong Kong Auto Stock News

Chow Tai Fook Jewellery Group (SEHK:1929) recently reported unaudited sales for the quarter to June 30, 2026, with group retail sales value up 15.1% year on year, drawing fresh attention to the stock. See our latest analysis for Chow Tai Fook Jewellery Group. The June quarter sales update has coincided with a pick up in momentum for Chow Tai Fook Jewellery Group, with a 1 month share price return of 8.27% and a 3 year total shareholder return of 15.33%. This is despite the 1 year total...

China Shanshui Cement Group’s share price sat at HK$0.241 going into the close on 6 August, with the stock flat over 7 days and down sharply over 3 months. The real story in this earnings print is the profit squeeze. Revenue in Q2 2026 reached ¥2,898.6m, yet the company still reported a net loss of ¥9.4m, capping a trailing twelve month loss of ¥1,458.5m. That mix of low sales multiple and ongoing losses is what the market is wrestling with, and it sets the emotional tone for how this result...

Hongkong and Shanghai Hotels stock finished today at HK$5.92, roughly flat over the week after a small 7 day pullback and a stronger 30 day run. The share price moved while the real story sat in the earnings. The group has reported a return to profit over the last 12 months, supported by a HK$414.0m one off gain, and now trades on a P/E of 15.6x. For short term traders the question is how durable that profit looks once the one off fades. For longer term holders the focus shifts to whether the...

In the half year to June 30, 2026, Prada S.p.A. reported sales of €2,931.97 million and revenue of €3,048.01 million, while net income fell to €326.86 million and basic earnings per share from continuing operations eased to €0.128. This mix of higher top-line performance but lower profitability raises questions about cost pressures and efficiency at a time when the group is investing heavily in growth initiatives. We’ll now examine how rising revenue but softer net income shapes Prada’s...

Uni-President China Holdings shares have drifted lower over the past week and quarter, yet the latest half year earnings tell a more nuanced story. The stock closed at HK$7.47 on 6 August, with recent returns under pressure, while trailing 12 month earnings per share sit at ¥0.501. That supports a P/E of 12.8x, above both peer and Hong Kong food industry averages, even as the company carries a high 7.38% dividend yield that is not well covered by recent earnings. For long term investors, the...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) is back in focus after Chinese regulators accepted a new indication application for its TROP2-directed ADC sacituzumab tirumotecan in first-line triple-negative breast cancer. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The regulatory momentum around sacituzumab tirumotecan and SKB565 comes alongside a 26.81% year to date share price return and a very large 3 year total shareholder return of about 7x. This suggests...

The market has spent the past week edging away from Far East Horizon, with the stock down around 8% over seven days and still sitting near HK$6.53 despite trading on a single digit P/E close to peers and far below industry levels. Yet the H1 2026 numbers tell a more stubborn story of earnings resilience. Net income from ongoing operations for the trailing twelve months stands at roughly C¥3.9b and basic earnings per share sit near C¥0.84. The real question now is whether today’s cool reaction...

Cathay Pacific Airways stock has been grinding higher in recent weeks, yet the real story sits in the earnings tape. The airline now trades on a trailing P/E of 6.9x while carrying a 12 month net margin of 10.3%. That is unusually lean pricing for a flag carrier delivering double digit profitability. The headline from this half year is simple. Profitability held up and earnings over the last year rose, while the share price at HK$15.14 still reflects an airline investors are treating with...

Essex Bio-Technology just closed at HK$2.39, capping a 90 day slide of about 24%, yet the latest half year report tells a more nuanced story than the share chart suggests. The stock still sits on a P/E near 5x while the business continues to generate hundreds of millions of Hong Kong dollars in revenue. The real headline from this earnings release is margin pressure. Net profit margin now sits at 15.4%, down from 18.2% a year ago. This puts the quality of those low multiples under the...

In recent weeks, global markets have experienced mixed movements, with major U.S. indices like the S&P 500 and Nasdaq Composite advancing, while the S&P MidCap 400 saw declines amid ongoing volatility related to central bank policies and geopolitical tensions. As small-cap stocks navigate these turbulent waters, investors often seek opportunities in companies that demonstrate resilience through strong fundamentals and strategic insider action.

In July 2026, Meitu’s AI-powered brand Wink expanded its creative toolkit, integrating AI video and image enhancement, editing, and content cleanup into a single connected workflow aimed at creators, small businesses, ecommerce sellers, marketers, and everyday users. This move meaningfully broadens Meitu’s AI imaging ecosystem by turning Wink into a one-stop platform that can repurpose and upgrade existing visual assets, potentially deepening user engagement across both professional and...

As Asian markets navigate a landscape marked by global economic shifts and technological advancements, investors are increasingly drawn to companies that demonstrate robust growth potential and strong insider confidence. In this environment, stocks with high insider ownership are often seen as promising opportunities, reflecting the belief of those closest to the company in its future prospects.

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Insiders who acquired CN¥99.4m worth of China NT Pharma Group Company Limited's ( HKG:1011 ) stock at an average price...

The market seemed underwhelmed by last week's earnings announcement from Bosideng International Holdings Limited...

Golden Resources Development International Limited ( HKG:677 ) just reported healthy earnings but the stock price...

While China International Development Corporation Limited ( HKG:264 ) shareholders have had a good week with the stock...

SUNeVision Holdings Ltd. ( HKG:1686 ), might not be a large cap stock, but it saw a double-digit share price rise of...

The market seemed underwhelmed by last week's earnings announcement from Four Seas Mercantile Holdings Limited...

Yeebo (International Holdings) Limited's ( HKG:259 ) stock wasn't much affected by its recent lackluster earnings...

China International Capital (SEHK:3908) moved to expand its international footprint with the launch of an asset custody service in Hong Kong, unveiled at its inaugural Embark Salon on 30 July. See our latest analysis for China International Capital. At a share price of HK$22.1, China International Capital has a 1-day share price return of 2.50% and a year-to-date share price return of 9.51%. Its 1-year total shareholder return of 11.58% and 3-year total shareholder return of 33.05% point to...

Even though Asia Allied Infrastructure Holdings Limited's ( HKG:711 ) recent earnings release was robust, the market...

As we navigate the diverse landscape of Asian markets, investors are keenly observing how global economic shifts and regional developments influence market dynamics. Penny stocks, a term that may seem outdated but remains relevant, often refer to smaller or newer companies offering growth opportunities at lower price points. When these stocks are supported by strong financial health and solid fundamentals, they can present an appealing mix of affordability and potential upside for investors...

In late July 2026, Keymed Biosciences announced positive global Phase III results for CMG901 (sonesitatug vedotin, AZD0901) in CLDN18.2-positive advanced gastric and related cancers, alongside Breakthrough Therapy Designation in China for its bispecific antibody CM512 in chronic rhinosinusitis with nasal polyps. These developments highlight Keymed’s progress in both oncology and immunology, anchored by its AstraZeneca partnership and a growing late-stage pipeline of first-in-class or highly...